$FC

FRANKLIN COVEY CO (FC): Results of Operations and Financial Condition

FRANKLIN COVEY CO (FC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 fc-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Press Release 13907 S. Minuteman Drive, Suite 500 Draper, UT 84020 www.franklincovey.com FRANKLIN COVEY REPORTS THIRD QUARTER FISCAL 2026 FINANCIAL RESULTS Consolidated Third Quarter Revenue Increases 1% to $67.8 Million Invoic

Original reporting
Published Jul 1, 2026, 8:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$FC
Neutral
medium confidence
Mentioned
$FC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FCNeutralMed
01

Why it matters

The key tradable update is the fiscal 2026 revenue guidance reduction, attributed to (1) timing shifts in Enterprise North America services delivery, (2) a last-minute state budget reduction impacting a large Education contract expected to return next year, and (3) a challenging international environment tied to geopolitical tensions. Adjusted EBITDA guidance is maintained within a narrower range, and deferred revenue increased, which may cushion the revenue reset.

02

Market read

Traders can reprice FC around the guidance change and the stated drivers, especially the revenue timing shift versus underlying demand signals (invoiced growth, deferred revenue).

03

What to watch

Free cash flow turned negative in the quarter and cash balance declined sharply; traders may need to watch working-capital swings and whether the Education budget headwind reverses as management expects next year.

Relevance 7/10Novelty 7/10Timing: after-hours/filing today (SEC 8-K) ahead of the July 1 earnings call

Background

This is an SEC 8-K (Item 2.02) with the company’s Q3 FY2026 financial results and a fiscal 2026 guidance revision.

Company-level read

Ticker impact

$FCNeutralMedium confidence
Context

Franklin Covey reported Q3 FY2026 results and revised fiscal 2026 revenue guidance to $260M–$267M from $265M–$275M.

Expected impact

Near-term downside bias versus prior expectations, with stabilization if investors focus on maintained Adjusted EBITDA guidance and deferred revenue growth.

Evidence & confidence

The filing is a primary earnings/guidance update with specific revised ranges and stated drivers (service delivery timing, Education contract funding delay, international environment). However, the article lacks consensus/market reaction context and provides limited detail on magnitude of cash flow deterioration beyond the quarter.

Market effects

Could modestly affect sentiment toward small-cap business-services/education training providers by highlighting revenue timing variability and budget-driven contract risk.

North America invoiced amounts grew 4% and deferred revenue rose, partially offset by weaker international segment revenue amid geopolitical tensions.

Limited broader index impact; mainly a single-name read-through on how geopolitical uncertainty and public-sector budgets affect training demand.

Counterpoint

The revenue guidance cut may be largely timing-related (services delivery shifting to next year) rather than demand deterioration, supported by higher deferred revenue and multi-year contract mix.

Key entities

  • Franklin Covey Co.

    Reported Q3 FY2026 results and revised fiscal 2026 revenue guidance; maintained Adjusted EBITDA guidance.

Related articles

$FCMed

Franklin Covey Co. Q3 2026 Earnings Call Summary

Franklin Covey Co. reported Q3 2026 momentum driven by higher client retention/expansion and North America enterprise growth, including a third straight quarter of rising invoiced amounts. Services booking pace rose 25% YTD. Fiscal 2027 outlook calls for faster revenue growth and operating leverage, but revenue guidance was cut ~$6M due to timing, education budget, and geopolitical impacts; gross margin fell to 73.9% from 76.5%.

$FCMedAI 8/10

Why Franklin Covey Stock Plummeted Today

Franklin Covey (FC) shares fell 12.9% on Thursday after the company reported Q3 FY2026 results (ended May 31) below Wall Street expectations and issued weaker-than-expected forward guidance. EPS was $0.27 on sales of $67.8M vs estimates of about $0.31 on ~$68.3M revenue; guidance called for $260M–$267M sales vs prior $265M–$275M.

$NVOHighAI 8/10

Novo Nordisk shares fall by up to 7% in Denmark — CNBC

Novo Nordisk shares dropped 7% in early trading on September 21, 2026, after the company announced new growth targets for its obesity treatment drugs. The firm aims to launch over five potential multi-blockbuster drugs by 2030 and expects sales of over 150 billion Danish kroner ($23 billion) by 2035. Novo Nordisk also anticipates matching industry revenue growth rates from 2026 to 2030.

$TCOMMed

Citi is bullish on these 2 Chinese travel stocks heading into the autumn holidays

Citi reiterated Buy ratings on Tongcheng (THG) and Trip.com (TCOM), citing attractive valuations and upcoming holidays as potential catalysts. Tongcheng reported Q2 2026 revenue of RMB 5.0 billion and net profit of RMB 851 million. Trip.com faces near-term headwinds but is expected to outperform in 2027. Analysts adjusted TCOM's price target to $60, maintaining Buy ratings.